Overcoming the skin permeation barrier: Challenges and opportunities

Current Pharmaceutical Design

Volumn 21, Issue 20, 2015, Pages 2698-2712

  Vitorino, Carla ^a,b   Sousa, João ^a,b   Pais, Alberto ^b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Active methods; Chemical penetration enhancers; Lipid nanoparticles; Microneedles; Passive methods; Permeation enhancement; Transdermal delivery

Indexed keywords

ALCOHOL; CERAMIDE; DRUG VEHICLE; LIPOSOME; NANOCARRIER; PENETRATION ENHANCING AGENT; POLYMER; SOLID LIPID NANOPARTICLE; TERPENE DERIVATIVE; DRUG;

ARTICLE; CHEMICAL STRUCTURE; DERMIS; DRUG FORMULATION; DRUG PENETRATION; ELECTROPORATION; EPIDERMIS; HUMAN; IONTOPHORESIS; MAGNETOPHORESIS; MICROEMULSION; MICRONEEDLE; PHOTOMECHANICAL WAVE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SKIN ABSORPTION; SKIN APPENDAGE; SKIN FUNCTION; SKIN PENETRATION; SKIN PERMEABILITY; SKIN STRUCTURE; SONOPHORESIS; STRATUM CORNEUM; SUBCUTANEOUS TISSUE; TRANSDERMAL DRUG ADMINISTRATION; ULTRASOUND; ANATOMY AND HISTOLOGY; ANIMAL; CHEMISTRY; CUTANEOUS DRUG ADMINISTRATION; DRUG DELIVERY SYSTEM; METABOLISM; PERMEABILITY; PHYSIOLOGY; PROCEDURES; SKIN; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, CUTANEOUS; ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; SKIN; SKIN ABSORPTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84930883529     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150428124053     Document Type: Article

References (139)

1. Brown MB, Martin GP, Jones SA, Akomeah FK. Dermal and transdermal drug delivery systems: current and future prospects. Drug Deliv 2006; 13: 175-87
2. Watkinson AC. Transdermal and Topical Drug Delivery Today. In: ed., Transdermal and Topical Drug Delivery. John Wiley Sons Inc 2011; pp: 357-66
3. Benson HAE. Skin Structure, Function, and Permeation. In: ed., Transdermal and Topical Drug Delivery. John Wiley Sons Inc 2011; pp: 1-22
4. Desai P, Patlolla RR, Singh M. Interaction of nanoparticles and cell-penetrating peptides with skin for transdermal drug delivery. Mol Membr Biol 2010; 27: 247-59
5. Elias PM. Stratum corneum defensive functions: an integrated view. J Invest Dermatol 2005; 125: 183-200
6. Elias PM. The skin barrier as an innate immune element. Semin Immunopathol 2007; 29: 3-14
7. Chilcott RP. Cutaneous Anatomy and Function. In: ed., Principles and Practice of Skin Toxicology. John Wiley Sons Ltd 2008; pp. 1-16
8. Riviere JE. Dermal Absorption Models in Toxicology and Pharmacology. Taylor Francis 2005
9. Kenneth W, Michael R. The Structure and Function of Skin. In: ed., Dermatological and Transdermal Formulations. Informa Healthcare 2002
10. Alexander A, Dwivedi S, Ajazuddin, et al. Approaches for breaking the barriers of drug permeation through transdermal drug delivery. J Control Release 2012; 164: 26-40
11. Bouwstra JA, Ponec M. The skin barrier in healthy and diseased state. Biochimica et Biophysica Acta (BBA) - Biomembranes 2006; 1758: 2080-95
12. Madison KC. Barrier function of the skin: "la raison d'etre" of the epidermis. J Invest Dermatol 2003; 121: 231-41
13. Lai-Cheong JE, McGrath JA. Structure and function of skin, hair and nails. Medicine 2009; 37: 223-226
14. Prow TW, Grice JE, Lin LL, et al. Nanoparticles and microparticles for skin drug delivery. Adv Drug Deliv Rev 2011; 63: 470-91
15. Zeeuwen PLJM. Epidermal differentiation: The role of proteases and their inhibitors. Eur J Cell Biol 2004; 83: 761-73
16. Hachem JP, Man MQ, Crumrine D, et al. Sustained serine proteases activity by prolonged increase in pH leads to degradation of lipid processing enzymes and profound alterations of barrier function and stratum corneum integrity. J Invest Dermatol 2005; 125: 510-20
17. Menon GK. New insights into skin structure: scratching the surface. Adv Drug Deliv Rev 2002; 54, (Suppl): S3-17
18. Tachibana T, Nawa T. Recent progress in studies on Merkel cell biology. Anat Sci Int 2002; 77: 26-33
19. Landmann L. The epidermal permeability barrier. Anat Embryol 1988; 178: 1-13
20. Egelrud T. Purification and preliminary characterization of stratum corneum chymotryptic enzyme: a proteinase that may be involved in desquamation. J Invest Dermatol 1993; 101: 200-4
21. Elias PM. Epidermal lipids, barrier function, and desquamation. J Invest Dermatol 1983; 80: 44s-9
22. Nemes Z, Steinert PM. Bricks and mortar of the epidermal barrier. Exp Mol Med 1999; 31: 5-19
23. Wickett RR, Visscher MO. Structure and function of the epidermal barrier. Am J Infect Control 2006; 34: S98-110
24. Lazo ND, Meine JG, Downing DT. Lipids are covalently attached to rigid corneocyte protein envelopes existing predominantly as beta- sheets: a solid-state nuclear magnetic resonance study. J Invest Dermatol 1995; 105: 296-300
25. Behne M, Uchida Y, Seki T, de Montellano PO, Elias PM, Holleran WM. Omega-hydroxyceramides are required for corneocyte lipid envelope (CLE) formation and normal epidermal permeability barrier function. J Invest Dermatol 2000; 114: 185-92
26. Coderch L, Lopez O, de la Maza A, Parra JL. Ceramides and skin function. Am J Clin Dermatol 2003; 4: 107-29
27. Masukawa Y, Narita H, Shimizu E, et al. Characterization of overall ceramide species in human stratum corneum. J Lipid Res 2008; 49: 1466-76
28. Darlenski R, Fluhr JW. Influence of skin type, race, sex, and anatomic location on epidermal barrier function. Clin Dermatol 2012; 30: 269-73
29. Silva CL, Nunes SCC, Eusébio MES, Sousa JJS, Pais AACC. Study of human stratum corneum and extracted lipids by thermomicroscopy and DSC. Chem Phys Lipids 2006; 140: 36-47
30. van Smeden J, Hoppel L, van der Heijden R, Hankemeier T, Vreeken RJ, Bouwstra JA. LC/MS analysis of stratum corneum lipids: ceramide profiling and discovery. J Lipid Res 2011; 52: 1211-21
31. Sato J, Denda M, Nakanishi J, Nomura J, Koyama J. Cholesterol sulfate inhibits proteases that are involved in desquamation of stratum corneum. J Invest Dermatol 1998; 111: 189-93
32. Norlen L, Nicander I, Lundsjo A, Cronholm T, Forslind B. A new HPLC-based method for the quantitative analysis of inner stratum corneum lipids with special reference to the free fatty acid fraction. Arch Dermatol Res 1998; 290: 508-16
33. Bouwstra JA, Honeywell-Nguyen PL, Gooris GS, Ponec M. Structure of the skin barrier and its modulation by vesicular formulations. Prog Lipid Res 2003; 42: 1-36
34. Norlen L. Skin barrier structure and function: the single gel phase model. J Invest Dermatol 2001; 117: 830-6
35. Walters KA. Dermatological and Transdermal Formulations. Taylor Francis 2002
36. Trommer H, Neubert RHH. Overcoming the stratum corneum: the modulation of skin penetration. Skin Pharmacol Physiol 2006; 19: 106-21
37. Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci 2001; 14: 101-14
38. Bolzinger M-A, Briançon S, Pelletier J, Chevalier Y. Penetration of drugs through skin, a complex rate-controlling membrane. Curr Opin Colloid Interface Sci 2012; 17: 156-65
39. Hadgraft J. Skin deep. Eur J Pharm Biopharm 2004; 58: 291-9
40. Moser K, Kriwet K, Naik A, Kalia YN, Guy RH. Passive skin penetration enhancement and its quantification in vitro. Eur J Pharm Biopharm 2001; 52: 103-12
41. Batisse D, Bazin R, Baldeweck T. Influence of age on the wrinkling capacities of skin. Skin Res Technol 2002; 8: 148-54
42. Roskos K, Maibach H, Guy R. The effect of aging on percutaneous absorption in man. J Pharmacokinetics Biopharm 1989; 17: 617-30
43. Giusti F, Martella A, Bertoni L, Seidenari S. Skin barrier, hydration, and pH of the skin of infants under 2 years of age. Pediatric Dermatol 2001; 18: 93-6
44. Cua AB, Wilhelm KP, Maibach HI. Frictional properties of human skin: relation to age, sex and anatomical region, stratum corneum hydration and transepidermal water loss. Br J Dermatol 1990; 123: 473-9
45. Tupker RA, Coenraads PJ, Pinnagoda J, Nater JP. Baseline transepidermal water loss (TEWL) as a prediction of susceptibility to sodium lauryl sulphate. Contact Dermatitis 1989; 20: 265-9
46. Gupta SK, Southam M, Gale R, Hwang SS. System functionality and physicochemical model of fentanyl transdermal system. J Pain Symptom Management 1992; 7: S17-26
47. Lane ME, Santos P, Watkinson AC, Hadgraft J. Passive Skin Permeation Enhancement. In: ed., Transdermal and Topical Drug Delivery. John Wiley Sons Inc 2011; pp: 23-42
48. Naik A, Kalia YN, Guy RH. Transdermal drug delivery: overcoming the skin’s barrier function. Pharm Sci Technol Today 2000; 3: 318-26
49. Finnin B, Walters KA, Franz TJ. In Vitro Skin Permeation Methodology. In: ed., Transdermal and Topical Drug Delivery. John Wiley Sons Inc 2011; pp: 85-108
50. Vitorino C, Almeida J, Gonçalves LM, Almeida AJ, Sousa JJ, Pais AACC. Co-encapsulating nanostructured lipid carriers for transdermal application: From experimental design to the molecular detail. J Control Release 2013; 167: 301-314
51. Adrian D, Robert G, Jonathan H, Mark P, Kenneth W. Formulation Strategies for Modulating Skin Permeation. In: ed., Dermatological and Transdermal Formulations. CRC Press 2002
52. Pellett MA, Castellano S, Hadgraft J, Davis AF. The penetration of supersaturated solutions of piroxicam across silicone membranes and human skin in vitro. J Control Release 1997; 46: 205-14
53. Morgan TM, O'Sullivan HMM, Reed BL, Finnin BC. Transdermal delivery of estradiol in postmenopausal women with a novel topical aerosol. J Pharm Sci 1998; 87: 1226-8
54. Marjukka Suhonen T, A. Bouwstra J, Urtti A. Chemical enhancement of percutaneous absorption in relation to stratum corneum structural alterations. J Control Release 1999; 59: 149-61
55. Stott PW, Williams AC, Barry BW. Transdermal delivery from eutectic systems: enhanced permeation of a model drug, ibuprofen. J Control Release 1998; 50: 297-308
56. Finnin BC, Morgan TM. Transdermal penetration enhancers: Applications, limitations, and potential. J Pharm Sci 1999; 88: 955-8
57. Barry BW. Lipid-Protein-Partitioning theory of skin penetration enhancement. J Control Release 1991; 15: 237-48
58. Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev 2004; 56: 603-18
59. Barry BW. Breaching the skin's barrier to drugs. Nat Biotechnol 2004; 22: 165-7
60. Almeida JAS, Marques EF, Jurado AS, Pais AACC. The effect of cationic gemini surfactants upon lipid membranes. An experimental and molecular dynamics simulation study. Phys Chem Chem Phys 2010; 12: 14462-76
61. Silva SC, Sousa JS, Marques E, Pais ACC, Michniak-Kohn B. Structure activity relationships in alkylammonium C12-gemini surfactants used as dermal permeation enhancers. AAPS J 2013; 15: 1119-27
62. Ongpipattanakul B, Burnette RR, Potts RO, Francoeur ML. Evidence that oleic acid exists in a separate phase within stratum corneum lipids. Pharm Res 1991; 8: 350-4
63. Hadgraft J. Passive enhancement strategies in topical and transdermal drug delivery. Int J Pharm 1999; 184: 1-6
64. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965; 13: 238-IN27
65. Gregoriadis G, Florence AT. Liposomes in drug delivery. Clinical, diagnostic and ophthalmic potential. Drugs 1993; 45: 15-28
66. Uchegbu IF, Florence AT. Non-ionic surfactant vesicles (niosomes): Physical and pharmaceutical chemistry. Adv Colloid Interface Sci 1995; 58: 1-55
67. Touitou E, Dayan N, Bergelson L, Godin B, Eliaz M. Ethosomes - novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J Control Release 2000; 65: 403-18
68. Cevc G. Transfersomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration, and transdermal drug delivery. Crit Rev Ther Drug Carrier Syst 1996; 13: 257-388
69. Honeywell-Nguyen PL, Bouwstra JA. Vesicles as a tool for transdermal and dermal delivery. Drug Discov Today: Technol 2005; 2: 67-74
70. Mezei M, Gulasekharam V. Liposomes - a selective drug delivery system for the topical route of administration I. Lotion dosage form. Life Sci 1980; 26: 1473-7
71. Bouwstra JA, Honeywell-Nguyen PL. Skin structure and mode of action of vesicles. Adv Drug Deliv Rev 2002; 54 (Suppl): S41-55
72. Cevc G, Blume G. New, highly efficient formulation of diclofenac for the topical, transdermal administration in ultradeformable drug carriers, Transfersomes. Biochimica et Biophysica Acta (BBA) - Biomembranes 2001; 1514: 191-205
73. Elsayed MMA, Abdallah OY, Naggar VF, Khalafallah NM. Lipid vesicles for skin delivery of drugs: reviewing three decades of research. Int J Pharm 2007; 332: 1-16
74. Kogan A, Garti N. Microemulsions as transdermal drug delivery vehicles. Adv Colloid Interface Sci 2006; 126: 369-85
75. Narasimha Murthy S, Shivakumar HN. Topical and transdermal drug delivery. In: Kulkarni VS, Ed. Handbook of Non-Invasive Drug Delivery Systems. Boston: William Andrew Publishing 2010; pp. 1-36
76. Lucks S, Müller R. Medication vehicles made of solid lipid particles (solid lipid nanospheres-SLN). In: ed., MEDAC Gesellschaft für klinische spezial präparate GmbH (Fehlandtstrasse 3, Hamburg, D-20354, DE) 1991
77. Mäder K, Mehnert W, Eds. Solid lipid nanoparticles—concepts, procedures, and physicochemical aspects, lipospheres in drug targets and delivery: approaches, methods, and applications. USA: CRC Press 2004
78. Lipid particles based on matrix comprising solid and liquid lipid, useful in diagnostics and for controlled release of active agents, especially pharmaceuticals
79. Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 2009; 366: 170-84
80. Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002; 54: S131-55
81. Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004; 56: 1257-1272
82. Rawat M, Singh D, Saraf S, Saraf S. Nanocarriers: Promising Vehicle for Bioactive Drugs. Biol Pharm Bull 2006; 29: 1790-8
83. Thassu D. Nanoparticulate drug delivery systems. New York: Informa Healthcare 2007
84. Mehnert W, Mäder K. Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev 2001; 47: 165-96
85. Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 2002; 242: 121-8
86. Teeranachaideekul V, Souto EB, Junyaprasert VB, Müller RH. Cetyl palmitate-based NLC for topical delivery of Coenzyme Q10 - Development, physicochemical characterization and in vitro release studies. Eur J Pharm Biopharm 2007; 67: 141-8
87. Muchow M, Maincent P, Müller RH. Lipid nanoparticles with a solid matrix (SLN®, NLC®, LDC®) for oral drug delivery. Drug Develop Ind Pharm 2008; 34: 1394-405
88. Müller RH, Shegokar R, Keck CM. 20 Years of Lipid Nanoparticles (SLN and NLC): Present state of development and industrial applications. Curr Drug Discov Technol 2011
89. Venkateswarlu V, Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release 2004; 95: 627-38
90. zur Mühlen A, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery - Drug release and release mechanism. Eur J Pharm Biopharm 1998; 45: 149-55
91. Souto EB, Wissing SA, Barbosa CM, Müller RH. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm 2004; 278: 71-7
92. Müller RH, Rühl D, Runge S, Schulze-Forster K, Mehnert W. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm Res 1997; 14: 458-62
93. Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev 2007; 59: 491-504
94. Bhaskar K, Mohan CK, Lingam M, et al. Development of SLN and NLC enriched hydrogels for transdermal delivery of nitrendipine: in vitro and in vivo characteristics. Drug Develop Ind Pharm 2009; 35: 98-113
95. Joshi M, Patravale V. Nanostructured lipid carrier (NLC) based gel of celecoxib. Int J Pharm 2008; 346: 124-32
96. Hasanovic A, Zehl M, Reznicek G, Valenta C. Chitosantripolyphosphate nanoparticles as a possible skin drug delivery system for aciclovir with enhanced stability. J Pharm Pharmacol 2009; 61: 1609-16
97. Rancan F, Papakostas D, Hadam S, et al. Investigation of polylactic acid (PLA) nanoparticles as drug delivery systems for local dermatotherapy. Pharm Res 2009; 26: 2027-36
98. Zhang W, Gao J, Zhu Q, et al. Penetration and distribution of PLGA nanoparticles in the human skin treated with microneedles. Int J Pharm 2010; 402: 205-12
99. Yiyun C, Na M, Tongwen X, et al. Transdermal delivery of nonsteroidal anti-inflammatory drugs mediated by polyamidoamine (PAMAM) dendrimers. J Pharm Sci 2007; 96: 595-602
100. Murthy SN, Sammeta SM, Bowers C. Magnetophoresis for enhancing transdermal drug delivery: Mechanistic studies and patch design. J Control Release 2010; 148: 197-203
101. Doukas AG, Kollias N. Transdermal drug delivery with a pressure wave. Adv Drug Deliv Rev 2004; 56: 559-79
102. Sá GFF, Serpa C, Arnaut LG. Stratum corneum permeabilization with photoacoustic waves generated by piezophotonic materials. J Control Release 2013; 167: 290-300
103. Arora A, Prausnitz MR, Mitragotri S. Micro-scale devices for transdermal drug delivery. Int J Pharm 2008; 364: 227-36
104. Grice JE, Prow TW, Kendall MAF, Roberts MS. Electrical and Physical Methods of Skin Penetration Enhancement. In: ed., Transdermal and Topical Drug Delivery. John Wiley Sons Inc 2011; pp. 43-65
105. Guy RH, Kalia YN, Delgado-Charro MB, Merino V, López A, Marro D. Iontophoresis: electrorepulsion and electroosmosis. J Control Release 2000; 64: 129-32
106. Silva SMC, Hu L, Sousa JJS, Pais AACC, Michniak-Kohn BB. A combination of nonionic surfactants and iontophoresis to enhance the transdermal drug delivery of ondansetron HCl and diltiazem HCl. Eur J Pharm Biopharm 2012; 80: 663-73
107. Denet A-R, Vanbever R, Préat V. Skin electroporation for transdermal and topical delivery. Adv Drug Deliv Rev 2004; 56: 659-74
108. Ogura M, Paliwal S, Mitragotri S. Low-frequency sonophoresis: Current status and future prospects. Adv Drug Deliv Rev 2008; 60: 1218-23
109. Joshi A, Raje J. Sonicated transdermal drug transport. J Control Release 2002; 83: 13-22
110. Smith NB. Perspectives on transdermal ultrasound mediated drug delivery. Int J Nanomed 2007; 2: 585-94
111. Tanner T, Marks R. Delivering drugs by the transdermal route: review and comment. Skin Res Technol 2008; 14: 249-60
112. van der Maaden K, Jiskoot W, Bouwstra J. Microneedle technologies for (trans)dermal drug and vaccine delivery. J Control Release 2012; 161: 645-55
113. Liu S, Jin MN, Quan YS, et al. The development and characteristics of novel microneedle arrays fabricated from hyaluronic acid, and their application in the transdermal delivery of insulin. J Control Release 2012; 161: 933-41
114. Benson HAE, Namjoshi S. Proteins and peptides: Strategies for delivery to and across the skin. J Pharm Sci 2008; 97: 3591-610
115. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol 2008; 26: 1261-8
116. Knorr F, Lademann J, Patzelt A, Sterry W, Blume-Peytavi U, Vogt A. Follicular transport route – Research progress and future perspectives. Eur J Pharm Biopharm 2009; 71: 173-80
117. Murthy SN, Sammeta SM, Bowers C. Magnetophoresis for enhancing transdermal drug delivery: Mechanistic studies and patch design. J Control Release 2010; 148: 197-203
118. Sammeta SM, Repka MA, Narasimha Murthy S. Magnetophoresis in combination with chemical enhancers for transdermal drug delivery. Drug Dev Ind Pharm 2011; 37: 1076-82
119. Menon GK, Kollias N, Doukas AG. Ultrastructural evidence of stratum corneum permeabilization induced by photomechanical waves. J Invest Dermatol 2003; 121: 104-9
120. Lee S, Doukas A. Laser-generated stress waves and their effects on the cell membrane. Selected topics in quantum electronics. IEEE J 1999; 5: 997-1003
121. Lin CH, Aljuffali IA, Fang JY. Lasers as an approach for promoting drug delivery via skin. Expert Opin Drug Deliv 2014; 11: 599-614
122. Nair VB, Panchagnula R. The effect of pretreatment with terpenes on transdermal iontophoretic delivery of arginine vasopressin. Il Farmaco 2004; 59: 575-81
123. Liu W, Hu M, Liu W, Xue C, Xu H, Yang X. Investigation of the carbopol gel of solid lipid nanoparticles for the transdermal iontophoretic delivery of triamcinolone acetonide acetate. Int J Pharm 2008; 364: 135-41
124. Tokudome Y, Sugibayashi K. Mechanism of the synergic effects of calcium chloride and electroporation on the in vitro enhanced skin permeation of drugs. J Control Release 2004; 95: 267-74
125. Seto JE, Polat BE, Lopez RFV, Blankschtein D, Langer R. Effects of ultrasound and sodium lauryl sulfate on the transdermal delivery of hydrophilic permeants: comparative in vitro studies with fullthickness and split-thickness pig and human skin. J Control Release 2010; 145: 26-32
126. Qin G, Gao Y, Wu Y, et al. Simultaneous basal-bolus delivery of fast-acting insulin and its significance in diabetes management. Nanomed: Nanotechnol, Biol Med 2012; 8: 221-227
127. Chen B, Wei J, Iliescu C. Sonophoretic enhanced microneedles array (SEMA)—Improving the efficiency of transdermal drug delivery. Sens Actuat B: Chem 2010; 145: 54-60
128. Wong T-W, Chen C-H, Huang C-C, Lin C-D, Hui S-W. Painless electroporation with a new needle-free microelectrode array to enhance transdermal drug delivery. J Control Release 2006; 110: 557-65
129. Tokumoto S, Higo N, Sugibayashi K. Effect of electroporation and pH on the iontophoretic transdermal delivery of human insulin. Int J Pharm 2006; 326: 13-9
130. Muller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs - a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol 2004; 113: 151-70
131. Jenning V, Schäfer-Korting M, Gohla S. Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties. J Control Release 2000; 66: 115-26
132. Müller RH, Petersen RD, Hommoss A, Pardeike J. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev 2007; 59: 522-30
133. Sanna V, Caria G, Mariani A. Effect of lipid nanoparticles containing fatty alcohols having different chain length on the ex vivo skin permeability of Econazole nitrate. Powder Technol 2010; 201: 32-6
134. Puglia C, Bonina F. Lipid nanoparticles as novel delivery systems for cosmetics and dermal pharmaceuticals. Expert Opin Drug Deliv 2012; 9: 429-441
135. Benson H. Transdermal drug delivery: penetration enhancement techniques. Curr Drug Deliv 2005; 2: 23-33
136. Vitorino C, Alves L, Antunes F, Sousa J, Pais ACC. Design of a dual nanostructured lipid carrier formulation based on physicochemical, rheological, and mechanical properties. J Nanoparticle Res 2013; 15: 1-14
137. Vitorino C, Sousa JJ, Pais AACC. A rapid reversed-phase HPLC method for the simultaneous analysis of olanzapine and simvastatin in dual nanostructured lipid carriers. Analytical Methods 2013; 5: 5058-64
138. Prausnitz MR. Microneedles for transdermal drug delivery. Adv Drug Deliv Rev 2004; 56: 581-7
139. Vitorino C, Almeida A, Sousa J, et al. Passive and active strategies for transdermal delivery using co-encapsulating nanostructured lipid carriers: in vitro vs. in vivo studies. Eur J Pharm Biopharm 2014; 86: 133-44.